Parathyroid hormone
As of the edition of 20 October 2026, Parathyroid hormone is a protein: marketed, first approved in 2015 (US); acts on PTH1R; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Protein
- Brand name
- Natpara
- First approved
- 23 January 2015 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Takeda
- Withdrawn from market
- 1 July 2026 (in some regions)
- Registered trials
- 36, 6 stopped early
- Disease areas
- Nutrition and metabolism; Bones, joints and muscles; Hormones; Injuries; Blood and lymph; Cancer
US protection
US protection ends in 2027.
US protection ends in 2027, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Takeda. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Parathyroid hormone.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | Q03431 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 1 | 9 | 6 | 0 | 2 |
| Phase 2 | 6 | 3 | 0 | 2 |
| Phase 3 | 14 | 11 | 0 | 2 |
| Phase 4 | 4 | 3 | 0 | 0 |
| All trials | 36 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Takeda | Acquired holder and Lead sponsor of trials | 1995 to now |